Brolucizumab Superior in Preserving Visual Acuity in Proliferative Diabetic Retinopathy

Why It Matters

Brolucizumab’s superior efficacy and safety could shift the treatment paradigm away from laser, offering diabetic patients a less invasive option that better preserves vision and reduces complications.

Key Takeaways

• Brolucizumab improved BCVA by +0.2 letters vs -4.2 with PRP
• No‑PDR patients rose to 187 on brolucizumab, 65 on PRP
• Center‑involved DME occurred in 31% of brolucizumab vs 73% PRP
• Ocular adverse events 34% with brolucizumab vs 49% PRP
• Study enrolled 689 adults across 16 countries, median age 54

Pulse Analysis

Diabetic retinopathy remains the leading cause of preventable blindness among working‑age adults, affecting roughly 22% of the global diabetic population. For decades, panretinal laser photocoagulation (PRP) has been the cornerstone of proliferative diabetic retinopathy (PDR) management, but the procedure carries risks such as visual field loss and choroidal effusions. The emergence of anti‑VEGF agents has offered a pharmacologic route, yet few have directly challenged PRP’s dominance in a large, randomized setting.

The CONDOR phase‑3 trial, spanning 152 sites in 16 countries, compared brolucizumab—a single‑chain antibody fragment—with PRP in treatment‑naïve PDR patients. Over 54 weeks, brolucizumab not only preserved visual acuity (+0.2 letters) but also reversed disease progression, increasing the number of eyes without PDR from 56 to 187, versus a modest rise to 65 with laser. The anti‑VEGF arm halved the incidence of center‑involved diabetic macular edema and reported fewer ocular and serious adverse events, underscoring a favorable safety profile.

If these results translate into real‑world practice, ophthalmologists may increasingly favor brolucizumab as a first‑line therapy, especially for patients reluctant to undergo laser. Payers will weigh the higher drug acquisition cost against potential savings from reduced vision‑threatening complications and fewer follow‑up procedures. Ongoing long‑term data will be critical to confirm durability, but the study positions brolucizumab as a compelling alternative that could reshape clinical guidelines and market dynamics in retinal disease care.